Acute myeloid leukemia (AML) is a cancer of immature blood cells. When the early myeloid cell matures normally, it will become either a mature white blood cell, red blood cell, or platelet.

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors ...

Here, we have assessed the expression of the Recepteur d’Origine Nantais (RON) in leukemic cell lines and samples from AML patients. In a series of 86 AML patients, we show that both the full ...

AML represents a disease that develops from the uncontrolled growth and survival of undifferentiated leukemia stem cells. These stem cells are particularly dependent for survival upon the MCL-1 ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Since cancer cells are, at their origin, also the body's own cells ... in NK cells that were specifically directed against AML cells. To that end, they cut the corresponding gene using the ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

FLT3 is expressed at very high levels on the cells of more than 80% of AML patients (irrespective of French-American-British subtype), of a fraction of acute lymphoblastic leukemia cells ...